Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2024-11-11 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2024-11-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Concord Biotech Limited to stock exchanges announcing an upcoming earnings call for the quarter and half year ended September 30, 2024. It includes details about the call date, time, participants, and dial-in information. The document does not contain actual financial results or detailed financial statements but serves as an invitation and notification of the earnings call event. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an invitation and announcement, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call event without substantive financial data or transcript content. The document length is 3322 characters, which is short and consistent with an announcement rather than a full report or transcript.
2024-11-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an invitation to an earnings call scheduled for November 12, 2024, to discuss the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. It includes details about the call, participants, and dial-in information. There are no actual financial results or detailed analysis presented in the document itself. The document is not the earnings release but an announcement of the earnings call event. Therefore, it fits the category of a Call Transcript (CT) invitation rather than the earnings release (ER) or interim report (IR).
2024-11-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter from Concord Biotech Limited addressed to stock exchanges notifying about an upcoming Board Meeting scheduled for November 11, 2024. The purpose of the meeting is to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2024, along with the limited review report by statutory auditors. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results or detailed financial data itself but is an announcement of the meeting where such results will be approved and likely released. The document length is short (2498 characters) and it serves as a notification rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification under SEBI regulations, rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-11-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2024. It is a compliance certificate confirming dematerialisation activities and related securities handling by the registrar and share transfer agent. The document is short (3610 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and regulatory confirmations.
2024-10-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.